Clinical Trials Logo

Clinical Trial Summary

A Phase I Clinical Study of Autologous T cells modified with chimeric antigen receptor targeting EpCAM ( EPCAM CAR-T) in Patients with malignant tumors of the digestive system (including advanced gastric cancer, colorectal cancer, liver cancer and pancreatic cancer) .


Clinical Trial Description

This is a phase I open-label, single and multiple infusion, dose escalation/cohort expansion study to evaluate the safety, cell pharmacokinetics, and preliminary efficacy of EPCAM CAR-T, infused intravenously in subjects who have been diagnosed with advanced malignant tumors of the digestive system (including advanced gastric cancer, colorectal cancer, liver cancer and pancreatic cancer) and refractory or intolerant to current standard systemic treatment. Primary objectives: •To evaluate the safety and tolerability of EPCAM CAR-T infused intravenously at escalating doses in patients with advanced malignant tumors of the digestive system. Secondary objectives: 1. The treatment of EpCAM CAR-T for patients with advanced digestive system malignancies, according to the dose-limiting toxicity and clinical response, including Possible side effects, determine the maximum tolerated dose (MTD), extended recommended dose (RDE) and/or recommended phase II dose (RP2D). 2. Assess the correlation between the pharmacodynamic (PD) biomarkers of IMC001 and clinical efficacy; EpCAM CAR-T expands and persists in vivo Correlation between sexual and pharmacodynamic (PD) biomarkers and adverse events. 3. To evaluate the preliminary anti-tumor efficacy of EpCAM CAR-T in patients with advanced digestive system malignancies. According to the evaluation criteria for the efficacy of solid tumors (RECIST) Version V.1.1, Evaluation Criteria for Efficacy of Immunotherapy for Solid Tumors (iRECIST), using objective response rate(ORR), duration of remission (DOR), disease control rate (DCR) and progression-free survival (PFS) description preliminary Anti-tumor activity. 4. The incidence of treatment-related adverse events. Exploratory purpose: 1. Assess changes in immune status of EPCAM CAR-T treatment. 2. Assess the change of CTC in the peripheral blood of patients and the clearance effect of CAR-T cell treatment on CTC. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05028933
Study type Interventional
Source Zhejiang University
Contact yuying zhao
Phone +86 15900830240
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date September 30, 2021
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04430452 - Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for the Treatment of Liver Cancer After Progression on Prior PD-1 Inhibition Phase 2
Recruiting NCT02632006 - Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT02638857 - Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT00752063 - Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma Phase 2
Completed NCT00517920 - Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC) Phase 2
Recruiting NCT01214343 - Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC Phase 3
Completed NCT00999882 - Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients Phase 1
Withdrawn NCT00756782 - A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma Phase 2
Completed NCT00534664 - Phase I/II Study of Amplitude-Modulated Electromagnetic Fields in the Treatment of Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT04503902 - Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Completed NCT04072679 - Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma Phase 1
Recruiting NCT04066660 - Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC) Phase 2
Completed NCT02528643 - A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma Phase 2
Recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1
Recruiting NCT04294498 - Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection Phase 2
Enrolling by invitation NCT04611165 - Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCC Phase 2
Not yet recruiting NCT04101747 - To Explore the Diversity of Intestinal Flora in Patients With Advanced HCC Combin ed With Anti-PD-1 and Targeted Drug Therapy and the Correlation Between Metabolites and Therapeutic Effect
Recruiting NCT04828486 - Futibatinib and Pembrolizumab for the Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer Phase 2
Recruiting NCT03605706 - A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment. Phase 3
Terminated NCT01942083 - A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma) Phase 1